CD8A and neoplasm: Given our observations, in addition to the recent observation that PDHc inhibition can increase CD8+ T cell cytotoxicity and increase immunotherapeutic efficacy47, and the ongoing clinical trials using PDHc inhibitors for several cancers48,49, we sought to determine the effects of DEG in tumour immunotherapy models.